Medpace Holdings, Inc. 10-Q

Item 5. Other Information During the three months ended June 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as described in the table below: -26- Table of Contents Action Date Trading Arrangement Total Shares to be Purchased or Sold Duration/Expiration Date Rule 10b5-1* Non-Rule 10b5-1** August J. Troendle , Chief Executive Officer and Chairman of the Board Adopt April 25, 2024 [1] X Up to 190,000 shares to be sold Good until cancelled August J. Troendle , Chief Executive Officer and Chairman of the Board Modify May 22, 2024 [2] X Up to 190,000 shares to be sold Good until cancelled August J. Troendle , Chief Executive Officer and Chairman of the Board Terminate May 30, 2024 [3] X Up to 190,000 shares to be sold Good until cancelled Susan E. Burwig , Executive Vice President, Operations Adopt June 5, 2024 [4] X Up to 7,681 shares to be sold The earlier of until cancelled or 180 days from the placement of the limit order * Intended to satisfy the affirmative defense of Rule 10b5-1(c). ** Not intended to satisfy the affirmative defense of Rule 10b5-1(c). [1] On April 25, 2024 , August J. Troendle placed a limit order to sell up to 190,000 shares that were previously acquired through various stock option exercises. Between April 25, 2024 and May 21, 2024, Mr. Troendle sold 142,250 shares pursuant to the limit order. [2] On May 22, 2024 , August J. Troendle changed the price limit for sales under the limit order originally adopted on April 25, 2024. [3] On May 30, 2024 , August J. Troendle terminated the limit order originally adopted on April 25, 2024. [4] On June 5, 2024 , Ms. Burwig placed a limit order to sell up to 7,681 shares that were acquired upon the vesting of restricted shares. Item 6. Exhibits The exhibits in the accompanying Exhibit Index preceding the signature page are filed or furnished as a part of this report and are incorporated herein by reference. -27- Table of Contents EXHIBIT INDEX Incorporated by Reference Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Filed/ Furnished Herewith 3.1 Restated Certificate of Incorporation 8-K 001-37856 3.1 5/21/2024 3.2 Second Amended and Restated Bylaws 8-K 001-37856 3.2 5/21/2024 31.1 Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer * 31.2 Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer * 32.1 Section 1350 Certification of Chief Executive Officer ** 32.2 Section 1350 Certification of Chief Financial Officer ** 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document * 101.SCH Inline XBRL Taxonomy Extension Schema Document * 101.CAL Inline XBRL Taxonomy Calculation Linkbase Document * 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document * 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document * 101.PRE Inline XBRL Taxonomy Extension Presentation * 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) * Filed herewith. ** Furnished herewith. -28- Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. MEDPACE HOLDINGS, INC. /s/ Kevin M. Brady Kevin M. Brady Chief Financial Officer (Principal Financial Officer) Date: July 23, 2024 -29-